ストックスクリーナーアプリを入手
114.75
0.53%
0.60
プレマーケット:
114.03
-0.72
-0.63%
Gilead Sciences Inc (GILD) 最新ニュース
Analyst Says Gilead (GILD) is a ‘Very High Quality’ Cheap Stock – Here’s Why - MSN
Stock Analysis | Gilead Sciences OutlookTechnical Neutrality and Mixed Analyst Signals - AInvest
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU - sharewise.com
Gilead's Lenacapavir Approved in EU for HIV Prevention - AInvest
Gilead Sciences’ HIV PrEP Injectable Approved by European Commission - PharmTech
Gilead Notches Another Win For 99.9% Effective HIV Drug - Investor's Business Daily
Visual trend scoring systems applied to Gilead Sciences Inc.Weekly Investment Report & Weekly Watchlist for Hot Stocks - Newser
Gilead's Lenacapavir Approved in Europe for HIV Prevention - AInvest
Gilead Sciences' Yeytuo: A Paradigm Shift in HIV Prevention and a Catalyst for Long-Term Profitability - AInvest
EU approves Gilead's new injection for preventing HIV - Reuters
Gilead Granted Marketing Authorization for Twice-Yearly HIV PrEP Shot in Europe - Contract Pharma
Gilead twice-yearly HIV PrEP drug OKed in EU (GILD:NASDAQ) - Seeking Alpha
Statistical indicators supporting Gilead Sciences Inc.’s strengthQuarterly Portfolio Review & Reliable Intraday Trade Plans - Newser
Gilead Sciences' Yeztugo: A Paradigm Shift in HIV Prevention and Investment Potential - AInvest
Gilead Sciences says European Commission authorizes twice-yearly Yeytuo for HIV prevention - MarketScreener
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention - Business Wire
Will Gilead Sciences Inc. stock recover after recent dropJuly 2025 Review & Weekly High Potential Stock Alerts - Newser
Gilead Sciences Redux: Why I'm Once Again Targeting This Big Pharma - TheStreet Pro
Will Gilead Sciences Inc. rebound enough to break evenLayoff News & Free Weekly Chart Analysis and Trade Guides - Newser
Will Gilead Sciences Inc. bounce back from current supportForecast Cut & Low Drawdown Momentum Trade Ideas - Newser
Gilead Sciences Advances Lung Cancer Treatment with New Clinical Study - TipRanks
Gilead Sciences Stock (GILD) Turns Negative As CVS Says No To HIV Prevention Drug - TipRanks
Gilead Sciences’ New HIV Treatment Study: A Potential Game-Changer? - TipRanks
Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius - BioPharma Dive
Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy - Benzinga
Why Gilead Sciences (GILD) Shares Are Sliding Today - Yahoo Finance
Coty, Gilead Sciences, Rent the Runway: Trending tickers - Yahoo Finance
Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million - statnews.com
Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists - Reuters
Gilead unit to acquire cell therapy developer Interius for $350 million - Reuters
Gilead Falls as CVS Hasn’t Yet Added PrEP HIV Shot to Drug Plans - Bloomberg
Gilead Sciences to Buy Interius BioTherapeutics for $350 Million - MarketScreener
Why Is Gilead Sciences Stock Falling Thursday?CVS Health (NYSE:CVS), Gilead Sciences (NASDAQ:GILD) - Benzinga
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform - Business Wire
Gilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition - MedCity News
From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave (NASDAQ:GILD) - Seeking Alpha
Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists By Reuters - Investing.com
Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD) - MSN
Ligand to Participate in September Investor Conferences - GlobeNewswire Inc.
We are positive on Gilead Sciences' base business growth: Meacham - BNN Bloomberg
Gilead attacks remdesivir patent of Chinese research institute at UPC - JUVE Patent
Insider Selling at Gilead Sciences: A Signal of Liquidity or a Cautionary Tale? - AInvest
Mizuho Securities Keeps Buy Rating on Gilead Sciences with $131 Target - AInvest
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
Gilead Sciences CCO Mercier sells $3.3m in shares - Investing.com
Gilead Sciences Inc. Stock Recovery Path — Analyst BreakdownJuly 2025 Outlook & Community Verified Swing Trade Signals - beatles.ru
Gilead Sciences CFO sells $296k in shares - Investing.com
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait? - Nasdaq
Sure, Biogen (BIIB) Has Been on a Hot Streak Recently But My Bet’s on Gilead Sciences (GILD) - Money Morning
Argus Adjusts Price Target on Gilead Sciences to $130 From $120 - MarketScreener
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use - PMLiVE
Gilead Sciences stock price target raised to $131 from $117 at Mizuho - Investing.com Canada
Mizuho Adjusts Price Target on Gilead Sciences to $131 From $117, Maintains Outperform Rating - MarketScreener
Gilead Sciences' Outperformance Means Overvalued (NASDAQ:GILD) - Seeking Alpha
Short Covering May Lift Gilead Sciences Inc. in Near TermJuly 2025 Patterns & Weekly High Return Forecasts - metal.it
What makes Gilead Sciences Inc. stock attractive todayJuly 2025 Review & Fast Moving Market Watchlists - thegnnews.com
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences Stock Surges in Trading Volume to 96th Rank Amid 0.55% Drop and Insider Sales - AInvest
Gilead Sciences Appoints New Senior Vice President - The Globe and Mail
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - MSN
Gilead Sciences and the Pricing Strategy of Lenacapavir: Balancing Profit and Public Health in the Fight Against HIV - AInvest
Gilead Sciences CEO Says HIV Prevention Drug Offers Clear Value - Bloomberg.com
Gilead Sciences' Triple Negative Breast Cancer Study: A Potential Game-Changer for the Oncology Sector - AInvest
Gilead Sciences Sees Decline in Short Interest, Market Sentiment Remains Unclear - AInvest
Gilead Sciences (GILD) Appoints New Senior Vice President and Pr - GuruFocus
0.88%
0.38%
大文字化:
|
ボリューム (24 時間):